Related Experiment Video
Updated: Jun 12, 2025
Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
Published on: June 6, 2020
Clinical effectiveness and implementation outcomes of pMDI-to-DPI switch in children between 5 and 12 years of age: a
Amanda Zain1,2, Alston Z Y Ng3, Inez Yeo3
1Centre for Sustainable Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore amandazain@nus.edu.sg.
Insights
This scoping review examines the clinical effectiveness of dry powder inhalers (DPIs) in children aged 5-12 with asthma. It synthesizes evidence on DPI use and implementation strategies for this age group.
Area of Science:
- Pediatric Respiratory Medicine
- Pharmacology and Therapeutics
Background:
- Inhaler misuse negatively impacts asthma management outcomes.
- Dry powder inhalers (DPIs) offer a safe and effective alternative to traditional metered-dose inhalers for adults and adolescents.
- Evidence for DPI clinical effectiveness in children aged 5-12 years with asthma is limited.
Purpose of the Study:
- To identify and synthesize evidence on the clinical effectiveness of DPI use in children aged 5-12 with asthma and other wheezing conditions.
- To outline implementation strategies and outcomes for prescribing or switching to DPIs in pediatric asthma patients.
Main Methods:
- A systematic and comprehensive literature search will be conducted across Medline, Embase, Cochrane Library, and CINAHL, including grey literature.
- Independent screening and data extraction by two review authors, with discrepancies resolved by consensus.
- Data charting, tabulation, and narrative summary by two independent reviewers.
Main Results:
- Evidence synthesis on DPI clinical effectiveness in children aged 5-12 years with asthma.
- Identification of implementation strategies and outcomes for DPI use in this pediatric population.
Conclusions:
- The review will provide a comprehensive overview of DPI effectiveness and implementation in children aged 5-12 years with asthma.
- Findings will inform clinical practice and potentially bridge the asthma care gap in younger populations.
- Results will be submitted for publication in a peer-reviewed scientific journal.
Introduction:
Inhalers are critical in asthma treatment, and inappropriate inhaler use leads to poor asthma outcomes. In adults and adolescents, dry powder inhalers (DPIs) are safe and effective alternatives to mainstay pressurised metered dose inhalers and could bridge the asthma care gap while also reducing the environmental burden of asthma care. Despite being licensed for use in ages 5 years old and older, the evidence for clinical effectiveness is less clear for patients between ages 5 and 12 years. This protocol describes a scoping review. The primary aim of the review is to identify and synthesise evidence on the clinical effectiveness of DPI use in children aged 5-12 years old with asthma and other wheezing conditions. The secondary aim of the review is to outline the implementation strategies and outcomes supporting the prescribing or switching to DPIs in children.
Methods And Analysis:
We will conduct a systematic and comprehensive literature search across four electronic databases (Medline, Embase, Cochrane Library and CINAHL) and grey literature. Screening and data extraction will be done independently by two review authors with discrepancies resolved through consensus. Data will be extracted and charted by two independent reviewers, then presented diagrammatically or tabulated with an accompanying narrative summary.
Ethics And Dissemination:
Ethical approval was not required for this study as it is a scoping review. The results of this scoping review will be submitted to a peer-reviewed scientific journal for publication.
